- Boehringer Ingelheim will invest £150 million in AI across R&D over 10 years to open a Computational Innovation centre in King's Cross, London.
- The UK hub will apply AI/ML to drug discovery and disease biology, expanding its Computational Innovation network with sites in Austria, Germany and the USA.
- The company expects the first 50 AI experts on site by the end of 2027.
Overview
Boehringer Ingelheim has opened a new Computational Innovation centre for AI and machine learning in King’s Cross, London, joining its existing sites in Austria, Germany and the USA and embedding in the Knowledge Quarter ecosystem to support pharmaceutical R&D.
Investment and timeline
The company plans a £150 million investment in AI across R&D over 10 years, with the first 50 AI specialists expected on site by the end of 2027.
Research focus
The London hub will develop foundational AI approaches to map patient journeys, uncover biological mechanisms that drive outcomes, identify primary causes of disease and improve target selection to accelerate discovery and decision-making.
Stakeholder engagement
The launch was marked by an event including government ministers, academic and technology representatives; UK Science Minister Lord Patrick Vallance said the hub will advance life‑science discovery and create highly skilled jobs.
